2025
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types
Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, Bratslavsky G, Braun D, Brugarolas J, Choueiri T, Finelli A, George D, Haas N, Hakimi A, Hammers H, Hirsch M, Jonasch E, Kapur P, Linehan W, Master V, McGregor B, McKay R, Mehra R, Pal S, Poteat S, Powles T, Rossi S, Shapiro D, Signoretti S, Singer E, Stravin C, Tannir N, Vaishampayan U, Xu W, Stewart G. A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types. European Urology 2025, 87: 385-389. PMID: 39855942, DOI: 10.1016/j.eururo.2025.01.007.Peer-Reviewed Original Research
2024
Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma
Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, Pruthi D, Bergerot C, Tripathi A, Lerner S, Thompson I, Lara P, Pal S. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma. JAMA Network Open 2024, 7: e2425288. PMID: 39106067, PMCID: PMC11304111, DOI: 10.1001/jamanetworkopen.2024.25288.Peer-Reviewed Original ResearchConceptsChromophobe renal cell carcinomaRecurrence-free survivalPapillary renal cell carcinomaRenal cell carcinomaNon-clear cell renal cell carcinomaResected renal cell carcinomaCell renal cell carcinomaOverall survivalWeeks of treatmentCell carcinomaAdverse eventsClinical trialsHazard ratioPhase 3 randomized clinical trialWeeks of everolimusHigher adverse eventsRate of adverse eventsIntermediate-high riskIntervention groupVery-high-riskCox regression modelsPotential treatment benefitsClinical trial dataTreatment-naivePartial nephrectomy
2023
Comparative evaluation of glomerular morphometric techniques reveals differential technical artifacts between focal segmental glomerulosclerosis and normal glomeruli
Reghuvaran A, Lin Q, Basgen J, Banu K, Shi H, Vashist A, Pell J, Perinchery S, He J, Moledina D, Wilson F, Menon M. Comparative evaluation of glomerular morphometric techniques reveals differential technical artifacts between focal segmental glomerulosclerosis and normal glomeruli. Physiological Reports 2023, 11: e15688. PMID: 37423891, PMCID: PMC10329935, DOI: 10.14814/phy2.15688.Peer-Reviewed Original ResearchPathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy
Panian J, Saidian A, Hakimi K, Ajmera A, Anderson W, Barata P, Berg S, Signoretti S, Chang S, D’Andrea V, George D, Dzimitrowicz H, Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus G, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay R. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. The Oncologist 2023, 29: 870-877. PMID: 37368355, PMCID: PMC11448883, DOI: 10.1093/oncolo/oyad166.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaProgression-free survivalAmerican Joint Committee on CancerAdvanced renal cell carcinomaCytoreductive nephrectomyPathological outcomesCell carcinomaMedian progression-free survivalPathologic outcomes of patientsCorrelated to clinical variablesRetrospective study of patientsEra of immunotherapySurgical pathology outcomeMedian follow-upResponse evaluation criteriaKaplan-Meier methodOutcomes of patientsTime of surgeryFraction of patientsStudy of patientsStandard of careIO monotherapyPathological downstagingCell histology
2022
External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study
Raheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.Peer-Reviewed Original ResearchConceptsNew-onset CKDCKD stageChronic kidney disease developmentExternal validationCKD stage ICT1 renal massesKidney disease developmentPreoperative eGFRPatient ageConsecutive patientsMulticenter studyTumor sizePartial nephrectomyRenal massesProgression rateGood calibration propertiesStage IProgression probabilityPatientsNomogramIndividual riskCKDDisease developmentEGFRMedian valueSafety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original ResearchKidney Biopsy Should Remain a Required Procedure for Nephrology Training Programs: COMMENTARY
Brewster U. Kidney Biopsy Should Remain a Required Procedure for Nephrology Training Programs: COMMENTARY. Kidney360 2022, 3: 1670-1671. PMID: 36515417, PMCID: PMC9717655, DOI: 10.34067/kid.0000872022.Peer-Reviewed Original ResearchThe Transplant Kidney Biopsy: In Whose Hands?
Virmani S, Kumar A. The Transplant Kidney Biopsy: In Whose Hands? Kidney360 2022, 3: 1662-1663. PMID: 36514728, PMCID: PMC9717671, DOI: 10.34067/kid.0005382022.Peer-Reviewed Original ResearchUpfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
Bakouny Z, Zarif T, Dudani S, Wells J, Gan C, Donskov F, Shapiro J, Davis I, Parnis F, Ravi P, Steinharter J, Agarwal N, Alva A, Wood L, Kapoor A, Morales J, Kollmannsberger C, Beuselinck B, Xie W, Heng D, Choueiri T. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology 2022, 83: 145-151. PMID: 36272943, DOI: 10.1016/j.eururo.2022.10.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaImmune checkpoint inhibitorsMetastatic renal cell carcinoma treated with immune checkpoint inhibitorsEra of immune checkpoint inhibitorsCheckpoint inhibitorsUpfront cytoreductive nephrectomyEffective systemic therapyCytoreductive nephrectomyTargeted therapySystemic therapyUpfront CNOS benefitOverall survivalInternational Metastatic Renal Cell Carcinoma Database ConsortiumPatients treated with immune checkpoint inhibitorsAssociated with significantly better OSInternational Metastatic RCC Database ConsortiumPatients treated with targeted therapyBenefit of CNModern systemic therapyTargeted therapy treatmentsMetastatic kidney cancerPrimary kidney tumorsKaplan-Meier methodRenal cell carcinomaComparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy
Tan W, Koelker M, Campain N, Cole A, Labban M, Mossanen M, Barod R, Kibel A, Chang S, Bex A, Trinh Q. Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy. European Urology Focus 2022, 9: 333-335. PMID: 36241545, DOI: 10.1016/j.euf.2022.09.018.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansKidneyKidney NeoplasmsMargins of ExcisionNeoplasm StagingNephrectomyConceptsRenal cell carcinomaLocally advanced kidney cancerPositive surgical marginsPartial nephrectomyAdvanced kidney cancerSurgical marginsKidney cancerRate of surgical marginComparison of long-term outcomesNational Cancer DatabaseMedian follow-upPatients aged <Cox proportional-hazards modelLong-term outcomesPresence of tumorCharlson Comorbidity IndexChronic kidney diseaseProportional-hazards modelCT1a tumorsCT1b groupHigher ACMNephron preservationCT stagingSolitary kidneyCell carcinomaThe Impact of Venous Thromboembolism on Mortality and Morbidity During Nephrectomy for Renal Mass
Patel HV, Sterling JA, Srivastava A, Ghodoussipour SB, Jang TL, Grandhi MS, August DA, Rahimi SA, Chung BI, Chang SL, Singer EA. The Impact of Venous Thromboembolism on Mortality and Morbidity During Nephrectomy for Renal Mass. Urology 2022, 168: 122-128. PMID: 35691439, DOI: 10.1016/j.urology.2022.05.033.Peer-Reviewed Original ResearchConceptsPreoperative venous thromboembolismTime of nephrectomyVenous thromboembolismRenal massesMajor complicationsRadical nephrectomyAssociation of VTEPresence of VTEConcurrent venous thromboembolismPremier Healthcare DatabaseDirect hospital costsMultivariable logistic regressionTypes of complicationsHigh rateICU admissionComplication rateSurgical resectionSurgical approachHospital costsNephrectomyPatientsHealthcare databasesComplicationsHigher overall costsLogistic regressionInflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease
Dejban P, Wilson E, Jayachandran M, Hernandez L, Haskic Z, Wellik L, Sinha S, Rule A, Denic A, Koo K, Potretzke A, Lieske J. Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease. Clinical Journal Of The American Society Of Nephrology 2022, 17: 414-422. PMID: 35078782, PMCID: PMC8975022, DOI: 10.2215/cjn.11730921.Peer-Reviewed Original ResearchConceptsRadical nephrectomy specimensUrinary stone diseaseNonstone formersStone formersStone diseaseInflammatory cellsNephrectomy specimensM1 macrophagesM2 macrophagesT lymphocytesMast cellsVascular disease statusInflammatory cell populationsBody mass indexAnti-inflammatory macrophagesInflammatory cell patternsAccumulation of proinflammatoryTumor characteristicsMass indexKidney tissueDisease statusMedullaAbstractTextCortexCalcificationDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive margins
2021
A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis
Psutka SP, Gulati R, Jewett MAS, Fadaak K, Finelli A, Legere L, Morgan TM, Pierorazio PM, Allaf ME, Herrin J, Lohse CM, Thompson R, Boorjian SA, Atwell TD, Schmit GD, Costello BA, Shah ND, Leibovich BC. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. European Urology 2021, 81: 576-585. PMID: 34862099, PMCID: PMC10351331, DOI: 10.1016/j.eururo.2021.11.002.Peer-Reviewed Original ResearchConceptsCancer-specific mortalityRenal cortical massesRadical nephrectomyPartial nephrectomyActive surveillancePersonalized treatment selectionClavien gradeRisk calculatorThermal ablationTreatment selectionEastern Cooperative Oncology Group performance statusClinical T1 renal massesSurgeon/hospital volumeHigh-volume referral centerInitial radical nephrectomyCharlson Comorbidity IndexCompeting-risks regressionConsecutive adult patientsGlomerular filtration rateClavien grade 3Risk of deathBody mass indexT1 renal massesRisk of mortalityClinical decision aidAMP-Kinase mediates regulation of glomerular volume and podocyte survival
Banu K, Lin Q, Basgen JM, Planoutene M, Wei C, Reghuvaran AC, Tian X, Shi H, Garzon F, Garzia A, Chun N, Cumpelik A, Santeusanio AD, Zhang W, Das B, Salem F, LI L, Ishibe S, Cantley LG, Kaufman L, Lemley KV, Ni Z, He JC, Murphy B, Menon MC. AMP-Kinase mediates regulation of glomerular volume and podocyte survival. JCI Insight 2021, 6: e150004. PMID: 34473647, PMCID: PMC8525649, DOI: 10.1172/jci.insight.150004.Peer-Reviewed Original ResearchAdenylate KinaseAdolescentAdultAgedAlbuminuriaAnimalsCell SizeCell SurvivalChildChild, PreschoolFemaleGene Knockdown TechniquesGlomerulonephritis, MembranousGlomerulosclerosis, Focal SegmentalHumansHypertrophyInfantKidney GlomerulusMaleMiceMicrofilament ProteinsMiddle AgedNephrectomyNephrosis, LipoidNephrotic SyndromePodocytesProportional Hazards ModelsProto-Oncogene Proteins c-fynYoung AdultChallenges in treatment of renal echinococcosis with gross hydatiduria and unsalvageable kidney: a case report
Shuaibi S, AlAshqar A, Alabdulhadi M, Al-Adsani W. Challenges in treatment of renal echinococcosis with gross hydatiduria and unsalvageable kidney: a case report. Journal Of Medical Case Reports 2021, 15: 487. PMID: 34587998, PMCID: PMC8479882, DOI: 10.1186/s13256-021-02992-2.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsEchinococcosisHumansKidneyKidney DiseasesKidney NeoplasmsMiddle AgedNephrectomyTomography, X-Ray ComputedConceptsRenal echinococcosisExtensive renal involvementCase presentationThisFlank painRenal involvementPositive serologyParenchymal destructionConclusionThis caseRenal scintigraphyCase reportProper counselingTherapeutic approachesDual pharmacotherapyPatientsSurgeryHydatiduriaPharmacotherapyEchinococcosisRare occurrenceChallenges physiciansExposure historyScientific evidenceSatisfactory responseTreatmentPhysiciansAdverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis
Yang C, Shuch B, Kluger HM, Serrano M, Kibel AS, Humphrey PA, Adeniran AJ. Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. American Journal Of Clinical Pathology 2021, 156: 550-558. PMID: 34424955, DOI: 10.1093/ajcp/aqab015.Peer-Reviewed Original ResearchConceptsPapillary renal cell carcinomaAdditional prognostic informationRenal cell carcinomaHistopathologic characteristicsTumor sizeCell carcinomaActive surveillancePrognostic informationRenal massesHigh World Health Organization/International SocietyWorld Health Organization/International SocietyLower disease-free survivalAdverse histologic featuresAdverse histopathologic featuresTumor histopathologic characteristicsUrological Pathology (ISUP) gradeDisease-free survivalDisease-specific survivalSmall renal massesWorse prognosisHistologic featuresHistopathologic featuresBiopsy examinationConsecutive casesHistologic diagnosisWarm ischemia time length during on-clamp partial nephrectomy: dose it really matter?
Abdel Raheem A, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, DE Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Tadifa J, Santok G, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Aguilera Bazan A, Ballesteros Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Alwahabi A, Alqahtani A, Rumaih A, Ghaith A, Ghoneem A, Hagras A, Eissa A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter? Minerva Urologica E Nefrologica 2021, 74: 194-202. PMID: 34308610, DOI: 10.23736/s2724-6051.21.04466-9.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesGlomerular Filtration RateHumansKidney NeoplasmsNephrectomyRetrospective StudiesWarm IschemiaConceptsClamp partial nephrectomyWarm ischemia timePartial nephrectomyEGFR preservationCKD stageEGFR valuesProgression rateGroup IILong-term renal functionGroup ILong-term renal function outcomeUnivariable Cox regression analysisMedian eGFR valueRenal function outcomesInternational cohort studyRenal functional recoveryCox regression analysisML/Regression analysisDisease upgradingEGFR declineEGFR changeCohort studyRenal functionFinal cohortDelayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic
Chan V, Tan W, Leow J, Tan W, Ong W, Chiu P, Gurung P, Pirola G, Orecchia L, Liew M, Lee H, Wang Y, Chen I, Castellani D, Wroclawski M, Mayor N, Sathianathen N, Braga I, Liu Z, Moon D, Tikkinen K, Kamat A, Meng M, Ficarra V, Giannarini G, Teoh J. Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. World Journal Of Urology 2021, 39: 4295-4303. PMID: 34031748, PMCID: PMC8143063, DOI: 10.1007/s00345-021-03734-1.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaLocalised RCCDelayed surgeryCytoreductive nephrectomyDeferred CNOverall survivalCell carcinomaTargeted therapyAssociated with worse cancer-specific survivalAssociated with better overall survivalT1a renal cell carcinomaEffect of delaying surgeryDeferred cytoreductive nephrectomyCancer-specific survivalMeta-analysisElective cancer surgeryNewcastle-Ottawa ScaleSystematic reviewComprehensive literature searchUpfront CNOncological effectivenessRisk of biasImmediate surgeryRandomised controlled trialsMayo Imaging Classification May Be Useful in Determining the Need for Nephrectomy in ADPKD.
Rosenberg S, Virmani S, Klarman S, Santovasi S, Dai F, Dahl NK. Mayo Imaging Classification May Be Useful in Determining the Need for Nephrectomy in ADPKD. Kidney360 2021, 2: 325-330. PMID: 35373011, PMCID: PMC8740992, DOI: 10.34067/kid.0003902020.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply